Dr. Agarwal's Health Care working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
165.00×165.00×180.74×
24.96×24.96×26.36×
286.17×286.17×344.62×
−96.21×−96.21×−137.52×
19.79×18.66×5.41×
0.55×0.55×0.47×
3.09×3.09×3.27×
0.91×0.91×0.79×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AGARWALEYE₹488.70

Dr. Agarwal's Health Care Ltd.

· Pharma & Health
₹ CrorePeersAKUMSADVENZYMESALIVUSAARTIPHARMAARTIDRUGSAPLLTDCORONAHCGMcap ₹15,482 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)180.74165.00165.00
Receivable Days (DSO)26.3624.9624.96
Payable Days (DPO)344.62286.17286.17
Cash Conversion Cycle (days)-137.52-96.21-96.21
Working Capital Turnover5.4118.6619.79
Asset Turnover0.470.550.55
Cash Conversion (CFO/Net Income)3.273.093.09
CFO/EBITDA0.790.910.91
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.